Skip to content
Open access

GATA2-driven ZNF486-JAM2 activation collaboratively counteracts epithelial-mesenchymal transition and in vitro invasion in endometrial cancer

Sep 2026 · Frontiers in Oncology · Vol 16 · 0 citations · 40 references
Medicine

TL;DR

GATA2 inhibits EMT, invasion, and migration in UCEC by transcriptionally activating the ZNF486-JAM2 axis and provides a potential molecular framework for understanding UCEC progression.

Abstract

Objective To investigate the role and molecular mechanism of the GATA2/ZNF486/JAM2 transcriptional regulatory axis in the invasion and migration of Uterine Corpus Endometrial Carcinoma (UCEC). Methods We employed reverse transcription quantitative polymerase chain reaction (RT-qPCR) and Western blot (WB) to assess the expression levels of ZNF486, GATA2, and JAM2 in UCEC cell lines. Lentivirus-mediated overexpression and knockdown cell lines were established, and CCK-8, colony formation, Transwell, and wound healing assays were performed to evaluate cell proliferation, invasion, and migration. WB and immunofluorescence were used to detect changes in epithelial-mesenchymal transition (EMT) markers. The direct binding and transcriptional activation of target gene promoters by transcription factors were confirmed through ChIP-qPCR and dual-luciferase reporter assays. Results ZNF486 was significantly downregulated in UCEC. Its overexpression upregulated E-cadherin, downregulated N-cadherin and Vimentin, and markedly inhibited cell proliferation, invasion, and migration. Mechanistically, ZNF486 directly bound to and transcriptionally activated the JAM2 promoter; knockdown of JAM2 partially attenuated the tumor-suppressive effects of ZNF486. Furthermore, GATA2 was identified as an upstream transcription factor that directly activated ZNF486 transcription; knockdown of ZNF486 abrogated the tumor-suppressive effects induced by GATA2 overexpression. Conclusion GATA2 inhibits EMT, invasion, and migration in UCEC by transcriptionally activating the ZNF486-JAM2 axis. This pathway provides a potential molecular framework for understanding UCEC progression.

Read PDF

Similar papers

Aug 2026

HOXC9 transcriptionally activates NRP1 to promote cell malignant progression and immune evasion in colorectal cancer

A specific mechanism whereby HOXC9 transcriptionally activates NRP1 is elucidated, thereby contributing to CRC malignant development and immune evasion and elucidate a specific mechanism whereby NRP1 overexpression could reverse CRC progression inhibition and immune function enhancement caused by HOXC9 downregulation.

Xiaofeng Qiu, Sheng Hu, Bingling Liao et al. · 0 citations
Sep 2026

CircARHGAP10 inhibits colorectal cancer cell proliferation, migration and invasion by governing the miR-29a-5p/LPP axis and regulating Wnt/β-catenin signaling pathway

It is revealed that circARHGAP10 functions as a tumor suppressor in CRC via two independent regulatory branches downstream of the circARHGAP10/miR-29a-5p cascade, and this newly identified circRNA-centered regulatory network provides a promising novel therapeutic target for CRC intervention.

Li-Yuan Liu, Yong-Cun Jia, Dong-Jie Li et al. · 0 citations
Open access Sep 2026

The RBP2–BECN1–VEGFA axis orchestrates a self-amplifying circuit to drive malignant progression in gastric carcinoma

Objective Gastric carcinoma (GC) is a leading cause of cancer-related mortality, often driven by epigenetic dysregulation. This study investigates the role of Retinoblastoma-binding protein 2 (RBP2), a chromatin-associated transcriptional regulator frequently overexpressed in GC. We specifically focus on elucidating ho...

Pan-Pan Tang, Ping Song, Xi-Zeng Li et al. · 0 citations
Open access Sep 2026

Exosomal circ-ZNF652 Mediates TGF-β1-Induced Epithelial-Mesenchymal Transition and Glycolytic Reprogramming to Promote Hepatocellular Carcinoma Progression

Exosomal circ-ZNF652 is associated with TGF-β1-induced mesenchymal phenotype acquisition and glycolysis via the AKT/HIF-1α pathway, promoting HCC progression and represents a potential non-invasive biomarker and therapeutic target for HCC.

Xian-Li Niu, Xiao-Min Zhang, Guang-Xia Liang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.